Hui Zhao

Hui Zhao is a Senior Director of Translational Biology at Exelixis, leading antibody-drug conjugate (ADC) biology and preclinical bioanalysis for drug discovery since August 2022. Previously, Hui served as Director of Biomarker Strategy at Ultragenyx Pharmaceutical Inc., overseeing biomarker strategies for rare diseases and authoring regulatory documents. Prior roles include Senior Principal Scientist at Bristol Myers Squibb, focusing on immuno-oncology projects, and Associate Principal Scientist at AstraZeneca, where Hui led a bioanalytical group. Hui's experience encompasses significant contributions to ADC translational research at Agensys, biomarker development at OSI Pharmaceuticals, and assay development at Pfizer. Hui holds a Ph.D. in Biochemistry & Molecular Biology from the University of Minnesota.